GLP-1s for MASH: Semaglutide and Tirzepatide in 2026

What MASH Actually Is

MASH stands for metabolic dysfunction-associated steatohepatitis. It was formerly called NASH (non-alcoholic steatohepatitis), and the naming changed as the field moved toward describing the condition by its metabolic drivers rather than by what it is not.

MASH sits on a broader spectrum called MASLD (metabolic dysfunction-associated steatotic liver disease). The progression is generally described in stages:

The reason fibrosis gets so much attention is that fibrosis stage, more than fat content alone, is the part most closely associated with long-term liver outcomes. That is why the regulatory and guideline conversation keeps circling back to whether a medication can affect fibrosis specifically, not just liver fat.

A critical compliance point worth stating plainly: staging MASH and fibrosis is a clinical process. It involves a clinician interpreting blood work, non-invasive scores, imaging, and sometimes biopsy together. No single number from a lab panel diagnoses or stages this condition.

The Semaglutide Approval (August 2025)

In August 2025, the FDA approved semaglutide (marketed as Wegovy) for adults with MASH and moderate-to-advanced fibrosis, to be used alongside diet and physical activity. This was a notable milestone because it was among the first GLP-1-based approvals to reach a liver indication rather than a weight or glucose indication.

The approval was supported by the ESSENCE trial, a Phase 3 program designed around liver-relevant endpoints. The headline reason this approval mattered to the field is that the program was structured to evaluate outcomes that regulators and hepatologists care about in MASH, including measures relevant to inflammation and fibrosis, rather than relying on weight change as a stand-in.

For people already familiar with [semaglutide](/peptides/semaglutide) in the weight and glucose context, the liver indication represents a distinct, separately-studied use. The medication is the same molecule, but the evidence base and the approved population for the MASH indication are specific.

The Tirzepatide Development (Early 2026)

[Tirzepatide](/peptides/tirzepatide) followed into the MASH conversation in early 2026. It received a breakthrough therapy designation for the indication, supported by data from the SYNERGY-NASH program.

Tirzepatide is a dual agonist, acting on both GIP and GLP-1 receptors, which is mechanistically different from semaglutide's single GLP-1 receptor agonism. SYNERGY-NASH reported encouraging results on MASH-related endpoints, which is what brought tirzepatide into the guideline discussion alongside semaglutide.

Here is where precision matters. The tirzepatide MASH data, while promising, is at an earlier stage than semaglutide's specifically when it comes to powered Phase 3 fibrosis outcomes. Both agents showed activity on MASH endpoints, but the depth and stage of the fibrosis-specific evidence differs between them as of 2026. Presenting that fairly is the responsible way to read the current landscape.

The 2026 EASO Guideline Split

The 2026 EASO guideline update is the document that pulled these two threads together. For the first time, it placed both semaglutide and tirzepatide into the liver-management algorithm for MASH.

But the update did not treat the two agents identically. It drew a distinction that mirrors the evidence:

This is the kind of nuance that gets flattened in headlines. The accurate takeaway is not "both drugs are now approved liver treatments and are interchangeable." It is closer to "both agents have entered the management algorithm, and the guideline explicitly notes that the fibrosis evidence is stronger for one than the other right now." That distinction is the single most important thing to carry away from this section.

### Semaglutide vs Tirzepatide for MASH: A 2026 Snapshot

|---|---|---|

This table is a snapshot of the reported regulatory and trial situation, not medical guidance. What any individual should do is a conversation with their clinician.

What to Track: Liver and Metabolic Biomarkers

This is where the discussion gets practical for anyone who wants to organize their own data over time. While diagnosis and staging belong to a clinician, the underlying biomarkers are things people routinely track between visits to see how their numbers move.

The commonly discussed liver and metabolic markers include:

Beyond single blood markers, clinicians use non-invasive scores and imaging to assess the liver more completely:

The point of tracking is not self-diagnosis. It is visibility. When you can see ALT, AST, triglycerides, HbA1c, and ApoB in one place across multiple blood draws, you and your clinician have a clearer trend to discuss. A single value on a single day tells you very little; a line over six months tells a story.

This is exactly the kind of work MyProtocolStack is built for. You can log your protocol, upload lab PDFs, and watch your markers trend over time instead of digging through scattered PDFs and portal screenshots. For a deeper walkthrough of enzyme monitoring, see [how to monitor liver enzymes on a protocol](/blog/how-to-monitor-liver-enzymes-on-protocol), and for GLP-1-specific lab context, the [tirzepatide blood work guide](/blog/tirzepatide-blood-work-guide). You can also browse the full [biomarkers library](/biomarkers) and [peptides directory](/peptides) to build out what you want to follow.

[Track your protocol and labs in one place with MyProtocolStack.](/auth/login?mode=signup)

How to Read the 2026 Landscape Without Overreaching

It is worth slowing down on language, because this is a topic where it is easy to overstate.

What the evidence supports saying:

What is not supported, and what no one should say:

The honest version is less dramatic but more useful. The field has moved meaningfully in two years, the evidence is stronger for one agent than the other on fibrosis specifically, and the practical action for an individual is to work with a clinician and keep a clear record of their own numbers over time.

Frequently Asked Questions

Is tirzepatide FDA-approved for MASH?

As of early 2026, tirzepatide received a breakthrough therapy designation for MASH and is advancing on the strength of SYNERGY-NASH data. The 2026 EASO guideline update included it in the liver-management algorithm. Its fibrosis-specific evidence is earlier-stage than semaglutide's. Confirm the current regulatory status and what it means for you with your clinician.

What is the difference between MASH and NASH?

MASH (metabolic dysfunction-associated steatohepatitis) is the current name for what was formerly called NASH (non-alcoholic steatohepatitis). The terminology shifted to describe the condition by its metabolic drivers. MASH sits within the broader MASLD spectrum and refers to the stage with fat plus inflammation and liver-cell injury.

Which liver biomarkers do people track on a GLP-1 protocol?

Commonly tracked markers include ALT, AST, and GGT (liver enzymes), plus metabolic markers like triglycerides, HbA1c, and ApoB. Clinicians also use non-invasive scores such as FIB-4 and ELF, and imaging like FibroScan and MRI-PDFF. Tracking shows trends over time; it does not diagnose or stage the condition, which is a clinical judgment.

Did semaglutide really get approved for fatty liver?

Semaglutide (Wegovy) received FDA approval in August 2025 for MASH with fibrosis, supported by the ESSENCE trial. It was among the first GLP-1-based approvals for a liver indication. The approval is specific to a defined population and is used alongside diet and physical activity.

Can I diagnose fatty liver from my own lab results?

No. MASH and fibrosis are diagnosed and staged by a clinician who interprets blood work, non-invasive scores, imaging, and sometimes biopsy together. Tracking your own ALT, AST, triglycerides, HbA1c, and ApoB is useful for seeing trends and having an informed conversation, but it is not a substitute for clinical assessment.

Sources

1. *AJMC, FDA approves semaglutide for MASH with fibrosis: https://www.ajmc.com/view/fda-approves-semaglutide-for-mash-with-fibrosis*

2. *Medscape, 2026 EASO update gives clearer roles for tirzepatide and semaglutide: https://www.medscape.com/viewarticle/easo-update-gives-clearer-roles-tirzepatide-semaglutide-2026a1000g7w*

3. *Metabolism Target and Organ Damage (OAE), GLP-1 in MASH 2026: https://www.oaepublish.com/articles/mtod.2026.13*

*This article is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment, and it does not constitute clinical decision support. MASH and fatty liver disease are diagnosed and managed by a qualified clinician. MyProtocolStack is a tracking and education tool for organizing and visualizing your protocol and lab data over time. Always consult your healthcare provider before making any decisions about medications, supplements, or your health.*